Neurocrine Biosciences (NBIX) Short-term Investments (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Short-term Investments for 17 consecutive years, with $57.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short-term Investments fell 91.93% year-over-year to $57.4 million; the trailing twelve-month figure through Jun 2026 stood at $57.4 million (down 91.93% YoY), and the FY2025 full-year result was $767.4 million, down 8.98% from the prior year.
• Short-term Investments declined to $57.4 million in Q2 2026 per NBIX's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $1.0 billion in Q1 2026 and bottomed at $57.4 million in Q2 2026.
• Historically, Short-term Investments has averaged $718.2 million across 5 years, with a median of $777.6 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Short-term Investments soared 100.35% in 2023, then slumped 91.93% in 2026.
• Over 5 years, Short-term Investments stood at $726.4 million in 2022, then grew by 7.45% to $780.5 million in 2023, then rose by 8.02% to $843.1 million in 2024, then fell by 8.98% to $767.4 million in 2025, then sank by 92.52% to $57.4 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $57.4 million, $1.0 billion, and $767.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.